CA2780541C - Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells - Google Patents

Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells Download PDF

Info

Publication number
CA2780541C
CA2780541C CA2780541A CA2780541A CA2780541C CA 2780541 C CA2780541 C CA 2780541C CA 2780541 A CA2780541 A CA 2780541A CA 2780541 A CA2780541 A CA 2780541A CA 2780541 C CA2780541 C CA 2780541C
Authority
CA
Canada
Prior art keywords
cells
grp
cultured
div
mammalian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2780541A
Other languages
English (en)
French (fr)
Other versions
CA2780541A1 (en
Inventor
Robert Sandrock
James T. Campanelli
Deborah A. Eppstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Q Therapeutics Inc
Original Assignee
Q Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Q Therapeutics Inc filed Critical Q Therapeutics Inc
Publication of CA2780541A1 publication Critical patent/CA2780541A1/en
Application granted granted Critical
Publication of CA2780541C publication Critical patent/CA2780541C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0622Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081Purging biological preparations of unwanted cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0623Stem cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
CA2780541A 2009-11-12 2010-11-09 Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells Active CA2780541C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26044109P 2009-11-12 2009-11-12
US61/260,441 2009-11-12
US32679910P 2010-04-22 2010-04-22
US61/326,799 2010-04-22
PCT/US2010/055956 WO2011059952A1 (en) 2009-11-12 2010-11-09 Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells

Publications (2)

Publication Number Publication Date
CA2780541A1 CA2780541A1 (en) 2011-05-19
CA2780541C true CA2780541C (en) 2015-07-14

Family

ID=43991980

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2780541A Active CA2780541C (en) 2009-11-12 2010-11-09 Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells

Country Status (11)

Country Link
US (2) US10351823B2 (https=)
EP (2) EP2499238B1 (https=)
JP (2) JP5952737B2 (https=)
CN (2) CN105602889A (https=)
AU (1) AU2010319680B2 (https=)
CA (1) CA2780541C (https=)
DK (1) DK2499238T3 (https=)
ES (1) ES2649396T3 (https=)
NO (1) NO2499238T3 (https=)
PL (1) PL2499238T3 (https=)
WO (1) WO2011059952A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070171A2 (en) 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
KR20110011658A (ko) 2008-05-08 2011-02-08 유니버시티 오브 로체스터 최적화된 세포 제제에 의한 수초 질환의 치료
JP6541577B2 (ja) 2013-02-06 2019-07-10 ユニバーシティー オブ ロチェスター ミエリン障害の治療のための誘導多能性細胞由来オリゴデンドロサイト前駆細胞
CA2959691A1 (en) * 2014-09-26 2016-03-31 The Procter & Gamble Company Products comprising malodor reduction materials
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
US11690876B2 (en) 2017-05-10 2023-07-04 University Of Rochester Methods of treating neuropsychiatric disorders
CN108624560B (zh) * 2018-06-01 2022-04-08 南京艾尔普再生医学科技有限公司 一种分化培养基及少突胶质前体细胞的制备方法
US10995325B2 (en) 2019-03-21 2021-05-04 Fornia Biosolutions, Inc. Additional phytase variants and methods
KR102322635B1 (ko) * 2021-06-11 2021-11-05 인제대학교 산학협력단 말초신경양 미세조직 제조방법 및 이의 용도
US20240254440A1 (en) * 2021-06-30 2024-08-01 The Regents Of The University Of California Methods to generate glial restricted neural progenitor cells and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235527B1 (en) * 1997-11-29 2001-05-22 University Of Utah Research Foundation Lineage restricted glial precursors from the central nervous system
CA2295197A1 (en) 1999-09-08 2001-03-08 Appleton Papers Inc. Thermally-responsive record material
US6878543B1 (en) * 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
AR046076A1 (es) * 2003-07-18 2005-11-23 Otsuka Pharma Co Ltd Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida
US20050272149A1 (en) * 2004-06-02 2005-12-08 Life & Brain Gmbh Therapeutic delivery of adenosine into a tissue
US20090155223A1 (en) * 2007-08-14 2009-06-18 The Johns Hopkins University Cell-based compositions and methods for treating conditions of the nervous system

Also Published As

Publication number Publication date
CN102686721B (zh) 2016-02-10
JP6346629B2 (ja) 2018-06-20
EP2499238A1 (en) 2012-09-19
HK1174953A1 (zh) 2013-06-21
EP2499238B1 (en) 2017-08-30
JP2016146831A (ja) 2016-08-18
EP3269803A2 (en) 2018-01-17
AU2010319680B2 (en) 2014-05-29
NO2499238T3 (https=) 2018-01-27
PL2499238T3 (pl) 2018-04-30
DK2499238T3 (en) 2017-12-04
ES2649396T3 (es) 2018-01-11
EP3269803A3 (en) 2018-04-25
WO2011059952A1 (en) 2011-05-19
US20120230963A1 (en) 2012-09-13
CN105602889A (zh) 2016-05-25
CA2780541A1 (en) 2011-05-19
EP2499238A4 (en) 2013-10-02
US10351823B2 (en) 2019-07-16
CN102686721A (zh) 2012-09-19
JP2013510570A (ja) 2013-03-28
AU2010319680A1 (en) 2012-07-05
US20190032010A1 (en) 2019-01-31
JP5952737B2 (ja) 2016-07-13

Similar Documents

Publication Publication Date Title
CA2780541C (en) Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells
CN103396993B (zh) 衍生自灵长类胚胎干细胞的用于脊髓损伤的再髓鞘化和治疗的少突胶质细胞
Faulkner et al. Human embryonic stem cell-derived oligodendrocyte progenitors for the treatment of spinal cord injury
Wang et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination
TWI586805B (zh) 獲得及維持在體外易於分化為寡樹突細胞-族系細胞之哺乳類神經幹細胞及/或神經祖源細胞的純或增富族群之培養方法
Mothe et al. Transplanted neural stem/progenitor cells generate myelinating oligodendrocytes and Schwann cells in spinal cord demyelination and dysmyelination
Sandner et al. Neural stem cells for spinal cord repair
US20110014695A1 (en) Methods for obtaining adult human olfactory progenitor cells
CA2489206C (en) Method for producing neural cell
Wang et al. Neurogenic potential of progenitor cells isolated from postmortem human Parkinsonian brains
KR20070109979A (ko) 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식
KR20230165846A (ko) 도파민성 전구세포 및 사용 방법
US7033995B2 (en) Production of radial glial cells
Liu et al. Characterization and therapeutic evaluation of a Nestin+ CNP+ NG2+ cell population on mouse spinal cord injury
HK1174953B (en) Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells
Khanna et al. Generation and transplantation of dopaminergic neurons derived from embryonic stem cells
CN1458273A (zh) 人胎儿背根神经节干细胞的分离、制备及应用
Canzi Human stem cells for the treatment of motorneuron diseases: regenerative potential, translatability and development of new biotechnologies. Cellule staminali umane per la cura delle malattie degenerative del motoneurone
HK1093219B (en) Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241105

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241105

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241107